SI
TCRR

Sofinnova Investments’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Sofinnova Investments’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-139,700
Closed -$2.29M – 87
2021
Q2 		$2.29M Buy
+139,700
New +$2.82M 0.13% 62

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Sofinnova Investments's TCRR Position: Q3 2021 in Review

Sofinnova Investments sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021, closing a stake of 296,282 shares — an estimated $4.86M sold.

Sofinnova Investments first reported a position in TCRR in Q3 2020 and held it in 4 quarters. The position peaked at $10.3M in Q4 2020. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

  • Sofinnova Investments reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Sofinnova Investments sold 296,282 TCR2 Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $4.86M.
  • Sofinnova Investments first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • Sofinnova Investments's TCR2 Therapeutics Inc. Common Stock position peaked at $10.3M in Q4 2020.
  • 117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.